Among them, 11 patients combined with the JAK2V617F mutation (6 ET and 5 PV), 2 ET patients combined with the CALR mutation, and 1 ET patient combined with the ASXL1 mutation. This evidence concerns the gene ASXL1 and essential thrombocythemia.